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Future trials aiming at patient selection outcomes will need
usable tissue from almost all patients, as well as a protocol design
and statistical plans that can accommodate the evolution of sci-
ence during the life of the trial. Patients entering trials are gener-
ally prepared to consent to tissue sampling after an appropriate
discussion with their treating physician. Most patients seem will-
ing to allow diagnostic biopsy tissues to be used for research, but
obtaining biopsies purely for research purposes is more challeng-
ing. Ethics boards may object to banking of tissues for future
undefined studies and focusing on the pathways of interest,
and careful consideration to the wording of the informed consent
can be very helpful in this regard. What is clear is that this is a
rapidly moving and important field and consultation between
academia, industry, regulators, ethics boards, patient advocates
and patients themselves is going to be key to improving the
acquisition of samples for future biomarker research, ultimately
leading to better targeted therapies.
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The speaker offered his personal viewpoint on validation of mul-
tiple biomarkers. Pharmaco-dynamic biomarkers have a role in
exploratory trials as markers of response and as proof of concept
for demonstrating drug activity. They can help establish the dose–
activity relationship in classical dose finding or phase II studies.
In exploratory trials, pharmacodynamic biomarkers may serve
as indicators of anti-tumour activity or as predictors of activity/
tolerance for future screening in confirmatory trials. Confirma-
tory trials may rely on biomarkers for qualitative screening to
determine which treatment is most appropriate for which
patients, or to indicate efficacy and safety. Biomarkers can also
be used in quantitative screening to establish dosing or as surro-
gate end-points to evaluate clinical benefit or harm. Because of
their importance in selecting patient populations and their rele-
vance in clinical trials of molecularly targeted agents, however,
biomarkers must be detected, selected and validated.
Biomarkers are more useful from a regulatory standpoint if
they have a biologically plausible basis, at least in theory. Regula-
tors also prefer biomarkers that give dichotomous answers (e.g.
yes/no; positive/negative) rather than relying on a semiquantita-
tive grading scale. Though in some cases, it is possible to trans-
form semiquantitative scores to binary ones. In any event,
developers and investigators should always keep inmindmultiple
pathways, time-related variability and inter-tumour differences.
Pharmacodynamic markers relate to effects that can be
observed through biology, biochemistry or imaging. They should
reflect an expected change related to the tested agent’s mecha-
nism of action. For example, reduced tumour blood flow by anti-
angiogenic agents, increased apoptosis by pro-apoptotic agents,
or changes in early or late effectors of a signal-induction pathway
(e.g. phosphorylation of a receptor leading to the inhibition of an
initiation factor). Pharmacodynamic markers should demon-
strate an effect on representative tissues (e.g. skin or oral mucosa
in the case of inhibitors of endothelial growth factor receptor). It
was emphasised that to regulators, it is not acceptable to define a
pharmacodynamic marker and use it for validation in the same
study.
Biomarkers can be an indicator of efficacy as a surrogate mar-
ker but cannot serve as a marker of clinical benefit per se. Ideally,
validation should be done prospectively, although initially, retro-
spective studies may be undertaken to identify surrogate mark-
ers. Circular validation is not acceptable as it would include
using individuals identified as biomarker-positive at interim anal-
ysis in the final validation analysis. Validation should be done in
another, complementary population that does not include the
original subpopulation found to be positive for the biomarker.
In another scenario it is possible that treatment does not have
a significant effect on overall survival in the entire population, but
a survival advantage is found among those who have a specific
biomarker. Such a scenario might be acceptable for registration
or licensure of the anticancer agent if the subpopulation were
pre-specified and if the difference in outcomes between the two
groups (biomarker-positive and -negative) was clear-cut. In prin-
ciple, regulatory authorities might want to avoid registering prod-
ucts that offer a benefit in overall survival only for the biomarker-
positive subpopulation. The difference between the treatment’s
effects on those with and without the biomarker would have to
be very clear.
Several definitions of surrogate end-point exist. According to
the Biomarkers Definitions Working Group, it is ‘a biomarker that
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is intended to substitute for a clinical end-point and is expected
to predict clinical benefit (or harm or lack of clinical benefit) based
on epidemiologic, therapeutic, pathophysiologic, or other scien-
tific evidence’.1 According to Fleming et al., ‘Any changes induced
in the surrogate end-point by a treatment must accurately reflect
changes in the true end-point’.2 Prentice et al. clarify that a surro-
gate end-point is ‘a response variable for which a test of the null
hypothesis of no relationship to the treatment groups under com-
parison is also a valid test of the corresponding null hypothesis
based on the true end-point’.3
Surrogate markers are quantitatively related to tumour bur-
den in all sites. Ideally, they should not be affected by subclonal
heterogeneity, and they should be assessable even at low tumour
burdens.
Surrogate markers are quantitatively related to tumour bur-
den in all sites. Ideally, they should not be affected by subclonal
heterogeneity, and they should be assessable even at low tumour
burdens. When selecting possible surrogate markers as clinical
trial end-points, investigators should weigh several important cri-
teria in order to collect data that will be relevant and sufficient for
subsequent licensure or registration of the anticancer agent. First,
is the potential surrogate biologically associated with the true
end-point? Second, is the treatment somehow associated with
the potential surrogate end-point? Third, does the potential sur-
rogate mediate the treatment’s effect on the true end-point and
is the potential surrogate biologically associated with the true
end-point?4
Under some circumstances the use of a surrogate end-point
might be misleading. For example, even with known perfect cor-
relation within randomized groups, one cannot rely on the poten-
tial surrogate end-point for valid inference about the true end-
point, because even the direction of their effects could be oppo-
site.5 Thus, even in preliminary trials, investigators should not
base conclusions on potential surrogate end-points if the valida-
tion is based solely on high correlation with the true end-point.
In conclusion, wemust agree on new rules that will allow us to
accept biomarkers at early stages of new drug investigations.
These biomarkers must correspond with some clinically relevant
measure, and their use must comply with the usual statistical
tools acceptable for new drug registration or licensure. The best
sort of trial to select and validate surrogate end-points is a com-
parative prospective trial that (1) determines the mean difference
and variance in the surrogate when the experimental and refer-
ence groups are compared, and (2) predicts the mean difference
and variance in the ideal true end-point when the experimental
and reference groups are compared. Such a trial might not save
time or spare patients, however, compared with a trial based on
conventional end-points.
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Drug development has progressed to the age of individualisation.
Therefore opportunities exist for applying biomarkers in this new
paradigm. Several definitions of relevant terms have been pro-
posed by the Biomarkers Definitions Working Group of the
National Institutes of Health (NIH) and the U.S. Food and Drug
Administration (FDA):
– A biological marker (biomarker) is ‘a characteristic that is
objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic
responses to a therapeutic intervention’.3
– A clinical end-point is ‘a characteristic or variable that reflects
how a patient feels, functions or survives’.3
– A surrogate end-point4 is ‘a biomarker that is intended to sub-
stitute for a clinical end-point. A surrogate end-point is
expected to predict clinical benefit or harm (or lack of benefit
or harm) based on epidemiologic, therapeutic, pathophysio-
logic, or other scientific evidence . . .Although all surrogate
end-points can be considered biomarkers, it is likely that only
a few biomarkers will achieve surrogate end-point status’.3
Pharmaceutical manufacturers, clinical investigators, and reg-
ulators rely on different types of biomarkers in the context of
drug development. Diagnostic biomarkers provide the means to
define a population with a specific disease. Prognostic biomarkers
correlate with outcomes. For example, over expression of her-2/
neu in breast cancer or epidermal growth factor receptor (EGFR)
expression in colorectal cancer indicates poor prognoses. In addi-
tion, tumour size, often assessed with radiographic tools, is a
prognostic marker because it correlates with outcome. Such prog-
nostic markers are frequently the basis for establishing inclusion
criteria for a clinical trial or for defining a patient population. Pre-
dictive biomarkers define populations that might respond more
favourably to a particular intervention from an efficacy or safety
perspective. They can be used to stratify patients for subgroup
analyses. Surrogates are biomarkers that correlate with clinical
benefit and changes in the marker correlate with alterations in
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